Please login to the form below

Not currently logged in
Email:
Password:

Syros appoints Moderna CEO to board

Stéphane Bancel also has experience at bioMérieux and Lilly
Syros Stephane Bancel

The founding CEO of Moderna Therapeutics, Stéphane Bancel, has joined the board of Syros Pharmaceuticals.

Syros, which focuses on controlling a person's genes to treat cancer and other diseases, will benefit from Bancel's work in RNA therapeutics at Moderna.

The company's CEO Nancy Simonian said: “Stéphane has established an exceptional track record of accomplishment in our industry. His successes in financing and building companies as well as in creating value are widely admired.”

Bancel joined Moderna in 2011, the year after its formation. Notable achievements as CEO include securing a licensing partnership with AstraZeneca potentially worth more than $400m.

Prior to serving as Moderna's CEO, Bancel spent four years as CEO of bioMérieux.

He also spent six years at Lilly, including a spell as country manager for Belgium.

Commenting on his appointment to the board of Syros, he said: “Syros' leadership in understanding gene control opens entirely new avenues to treat cancer and other serious diseases.

“The company's revolutionary approach creates significant opportunity to impact health and create value.”

27th November 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

Article: What's next? How behavioural science can support pharma's future
...
Video: UX/ Experience design research
...
White paper: The impact of COVID-19 on chronic disease management
...

Infographics